Business
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provided an update ...
About this update from Aspire Biopharma Holdings, Inc.
[{"type":"text","content":"HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provided an update on its two patent applications, originally filed as provisional patent applications with the U.S. Patent and Trademark Office ("USPTO") on March 31, 2023 and October 2, 2024, respectively, pertaining to Oral Mucosal Formulations of Aspirin that utilize Aspire's fast acting formulation.","length":567,"tagName":"p"},{"type":"text","content":"A provisional patent application is a critical step on the road to commercial viability. As the climate for intellectual property rights becomes increasingly competitive, a provisional patent application establishes an early effective filing date for any subject matter disclosed in the provisional application and allows the patent applicant or a licensee to ascribe the phrase "patent pending" to any product or method covered by the provisional application.","length":470,"tagName":"p"},{"type":"text","content":""The filing of these patent applications for our innovative drug delivery platform marks another important step in strengthening our intellectual property portfolio and potentially offers a rapid, cost-effective, and scalable way to produce a new therapeutic sublingual form of aspirin," commented Kraig Higginson, Chief Executive Officer of Aspire. "We believe that our technology has the potential to transform sublingual drug delivery by improving the efficacy and safety of a wide range of medications. We are committed to advancing the therapeutic applications of this innovative technology platform to address critical healthcare challenges and improve patient outcomes."","length":697,"tagName":"p"},{"type":"text","content":"The Company believes its patent pending technology is groundbreaking because it offers significant advantages over existing oral formulations of numerous prescription and non-prescription products due to its new mechanism of action (absorption pathway) which allows for rapid sublingual absorption. The benefits of "rapid absorption" are to provide nearly instant treatment impact and high dose absorption. The Company's patent pending delivery system in...